In the following tables, sales are disaggregated by category, sales by geographic market and sales by product data. The following breaks down sales into the following categories (in thousands):


	Three Months Ended
	March 29, 2024		March 31, 2023
Non-consignment sales	$	71,764	$	67,163
Consignment sales		5,592		6,365
Total net sales	$	77,356	$	73,528

The Company markets and sells its products in over 75 countries and conducts its manufacturing in the United States. Other than China and Japan, the Company does not conduct business in any country in which its sales exceed 10% of worldwide consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):


	Three Months Ended
	March 29, 2024		March 31, 2023
Domestic	$	4,935	$	4,551
Foreign:
China		38,549		35,090
Japan		10,456		10,936
Other(1)		23,416		22,951
Total foreign sales		72,421		68,977
Total net sales	$	77,356	$	73,528

(1)

No other location individually exceeds 10% of the total sales.

100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery. Historically the Company marketed and sold cataract intraocular lenses (“IOLs”) and related injectors and injector parts. The Company phased out sales of such products in fiscal 2023, and does not expect to sell any such products in fiscal 2024 or thereafter. The composition of the Company’s net sales by product line was as follows (in thousands):


	Three Months Ended
	March 29, 2024		March 31, 2023
ICLs	$	77,151	$	70,625
Other product sales:
Cataract IOLs		—		1,476
Other surgical products(1)		205		1,427
Total other product sales		205		2,903
Total net sales	$	77,356	$	73,528

(1) Other surgical products include delivery systems and normal recurring sales adjustments such as sales return allowances.

The Company’s China distributors accounted for 49% and 48% of net sales for the three months ended March 29, 2024 and March 31, 2023, respectively. As of March 29, 2024 and December 29, 2023, the Company’s China distributors accounted for 54% and 70%, respectively, of consolidated trade receivables.